

# GLOSSARY OF TERMS

<b>Acute coronary syndrome (ACS)</b>	ACS occurs when a coronary artery is blocked by a blood clot, reducing blood supply to the heart. ACS events include MI, commonly known as heart attack, and unstable angina (a very serious complication that indicates a heart attack could soon occur). ACS is a common and life-threatening result of coronary heart disease (CHD), which kills approximately 7.2 million people worldwide each year.
<b>Anticoagulant drugs</b>	Drugs designed to prevent and treat blood clots. Sometimes referred to as 'blood thinners'.
<b>Arthroplasty</b>	Surgical replacement of a joint.
<b>Atrial fibrillation (AF)</b>	A heart rhythm disorder where chambers in the upper heart (atria) beat more rapidly than those in the lower section of the heart. Blood is not pumped out of the upper chambers completely during beating, and may pool and form a clot. A stroke results if a section of clot dislodges from the upper chambers and becomes lodged in the brain.
<b>Coagulation cascade</b>	A chain of biochemical reactions that result in clot formation. Anticoagulants work by blocking or regulating a stage, or stages, of the coagulation cascade.
<b>Composite endpoint</b>	A combination of two or more endpoints in a clinical trial.
<b>Deep vein thrombosis (DVT)</b>	<p>A blood clot in a deep vein, usually resulting from damage to the vein or blood flow slowing down or stopping. Usually DVTs are found in the leg, but can also be in the arm.</p> <p><i>Distal</i> DVTs are found in deep veins of the calf, and are the most common type of DVT.</p> <p><i>Proximal</i> DVTs are found in the legs above the calf muscle up to the waist.</p>
<b>Drug–drug interaction</b>	A modification of the effect of a drug when administered with another drug, usually either an increase or decrease in the action of either substance, or an effect not normally associated with either drug alone.
<b>Efficacy</b>	The ability of a drug to produce the desired effect.
<b>Electrocardiogram</b>	A test that records the electrical activity of the heart, showing abnormal rhythms and detects heart muscle damage.
<b>Factor Xa</b>	Pivotal component of the blood clotting cascade. Stimulates the production of thrombin, the enzyme in the coagulation cascade that promotes the formation of blood clots.
<b>Factor Xa inhibitor</b>	An anticoagulant drug that targets the blood coagulation cascade at a pivotal point by inhibiting the production of thrombin, an enzyme that promotes blood clots.

<b>International Normalized Ratio (INR)</b>	A system for assessing the clotting tendency of blood in patients receiving anticoagulant therapy, including vitamin K antagonists (VKAs). For patients with atrial fibrillation, the recommended target INR range is between 2 and 3. If the INR is higher than 3, patients are at risk of serious bleeding. If the INR is less than 2, patients are at risk of a blood clotting event.
<b>Intravenous</b>	Within or administered into a vein.
<b>Low molecular weight heparin (LMWH)</b>	An anticoagulant used to prevent new clots forming and existing clots from getting larger. It is usually injected subcutaneously, though for ACS it is given intravenously.
<b>Major orthopedic surgery</b>	Major operations on the bones or joints, including total hip or knee replacement surgery.
<b>Pooled data analysis</b>	A statistical tool that combines the results of studies, for which the populations must be similar, that address a set of related principal outcomes. The resultant larger sample size allows less frequent events to be analyzed.
<b>Prothrombin</b>	Inactive version of thrombin, the enzyme in the coagulation cascade that promotes the formation of blood clots. Factor Xa stimulates the conversion of prothrombin to thrombin.
<b>Pulmonary embolism (PE)</b>	A potentially fatal condition caused by a blood clot blocking a vessel in the lung: usually the clot originates from a DVT in the legs. PE can result in permanent lung damage and, in some cases, death.
<b>Subcutaneous</b>	Introduced beneath the skin.
<b>Thrombin</b>	Enzyme in the blood clotting cascade that promotes the formation of blood clots.
<b>Thrombosis</b>	Formation of a clot (thrombus) inside a blood vessel, obstructing the flow of blood through the circulatory system.
<b>Thromboprophylaxis</b>	Preventative treatment for blood clotting.
<b>Venous thromboembolism (VTE)</b>	A disease process beginning with a blood clot occurring within the venous system, including deep vein thrombosis and pulmonary embolism.
<b>Vitamin K antagonist (VKA)</b>	The first oral anticoagulant on the market. The most common type is warfarin. VKAs work by blocking the ability of a vitamin K to regenerate, which eventually slows the activation of the coagulation cascade and the ultimate formation of blood clots.

To learn more about VTE please visit [www.thrombosisadviser.com](http://www.thrombosisadviser.com)

To learn more about 'Xarelto' please visit [www.xarelto.com](http://www.xarelto.com)